SCHEMBL3618668

SCHEMBL3618668

COc1cnc2ccc(Cl)c(O)c2n1

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
PTPN11 Q06124 7/20 0.35
KCNH2 Q12809 2/20 0.34
HTT P42858 2/20 0.33
AMY1A P0DUB6 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SRC P12931 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29692824 0.87 KCNH2 (0.36) PDGFRBPDGFRAKCNH2
SCHEMBL2770307 0.87 KCNH2 (0.36) PDGFRBPDGFRAKCNH2
SCHEMBL18544276 0.82 PDGFRB (0.36) CSF1RPDGFRBPDGFRAPTPN11KCNH2
SCHEMBL3346945 0.81 ERN1 (0.44) CSF1RPDGFRBPDGFRAHTTAMY1A
SCHEMBL5432490 0.79 PTPN11 (0.35) CSF1RPTPN11KCNH2
SCHEMBL5747243 0.79 KCNH2 (0.33) PTPN11KCNH2
SCHEMBL14372223 0.78 CSF1R (0.34) CSF1RPDGFRBPDGFRAPTPN11KCNH2
SCHEMBL14400283 0.78 KCNH2 (0.39) CSF1RPDGFRBPDGFRAPTPN11KCNH2
SCHEMBL13313305 0.78 MAPT (0.45) HTTALDH1A1
SCHEMBL5263274 0.77 CSF1R (0.34) CSF1RPDGFRBPDGFRAPTPN11KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087424-A1 TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED 2010-04-08 US disclosed
EP-2137195-A1 TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS Glaxo Group Limited (GB) 2009-12-30 EP disclosed
WO-2008128953-A1 TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2008-10-30 WO disclosed
US-20070244103-A1 Novel Compounds Having an Anti-Bacterial Activity MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2007-10-18 US disclosed
EP-1781650-A1 NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2007-05-09 EP disclosed
WO-2006021448-A1 NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087424-A1 TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS NRDC, NDC1, NANS CSF1R 2677/4885PDGFRB 2947/4885PDGFRA 2751/4885
US-20070244103-A1 Novel Compounds Having an Anti-Bacterial Activity TOP1, TOP2A, TOP2B CSF1R 2778/4885PDGFRB 4424/4885PDGFRA 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.